Total amount raised
$1.6 Billions
Latest funding date
Location
Tempus has successfully raised significant capital through multiple funding rounds, including a recent Post-IPO Debt round. The company leverages artificial intelligence to enhance precision medicine, offering innovative solutions for healthcare providers, life sciences, and patients.
Keep reading to explore the intricacies of Tempus' fundraising journey and the investors backing this transformative platform.
What Is Tempus?
Tempus, founded in August 2015 by Eric Lefkofsky, is headquartered in Chicago, Illinois. The company specializes in leveraging artificial intelligence to enhance precision medicine, aiming to transform healthcare through data-driven insights and advanced technology.
Tempus offers a range of services, including genomic profiling, clinical trial matching, AI-enabled algorithmic tests, and EHR integration. These solutions support healthcare providers, life sciences companies, and patients by providing personalized treatment options and accelerating drug development.
With a workforce of 1001-5000 employees, Tempus continues to innovate in the field of precision medicine, making significant strides in improving patient outcomes and advancing medical research.
How Much Funding Has Tempus Raised?
- Round Name: Series D
- Amount Raised: $80M
- Date: March 2018
- Lead Investors: T. Rowe Price
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand AI capabilities and enhance precision medicine offerings.
- Round Name: Series E
- Amount Raised: $110M
- Date: August 2018
- Lead Investors: Baillie Gifford
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and invest in new technology.
- Round Name: Series F
- Amount Raised: $200M
- Date: May 2019
- Lead Investors: Baillie Gifford
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate growth and expand market reach.
- Round Name: Series G
- Amount Raised: $100M
- Date: March 2020
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop AI-driven solutions.
- Round Name: Debt Financing
- Amount Raised: $250M
- Date: December 2020
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support ongoing research and development.
- Round Name: Series G
- Amount Raised: $200M
- Date: December 2020
- Lead Investors: Google
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance data infrastructure and AI capabilities.
- Round Name: Venture Round
- Amount Raised: $100M
- Date: October 2022
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand clinical trial matching services.
- Round Name: Debt Financing
- Amount Raised: $175M
- Date: October 2022
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support strategic acquisitions and growth.
- Round Name: Series G
- Amount Raised: Not publicly disclosed
- Date: October 2023
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To continue scaling AI-driven healthcare solutions.
- Round Name: Post-IPO Debt
- Amount Raised: $300M
- Date: February 2025
- Lead Investors: Ares Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund the acquisition of Ambry Genetics.
Tempus has raised a total of $1.515 billion in funding. The current valuation is not publicly disclosed.
Key Investors
- Ares Management
- Details: Ares Management is a global alternative investment manager. They have provided Tempus with significant debt financing, including a $300M package in February 2025.
- Investment Focus Areas: Credit, private equity, real estate.
- Notable Investments: Tempus, DuPage Medical Group, Guitar Center.
- Baillie Gifford
- Details: Baillie Gifford is an investment management firm based in Edinburgh, Scotland. They have been involved in multiple funding rounds for Tempus, including Series E and Series F.
- Investment Focus Areas: Technology, healthcare, consumer goods.
- Notable Investments: Tesla, Amazon, SpaceX.
- Google
- Details: Google, a subsidiary of Alphabet Inc., is a multinational technology company. They led the Series G round for Tempus in December 2020.
- Investment Focus Areas: Technology, artificial intelligence, healthcare.
- Notable Investments: Waymo, Verily, DeepMind.
- T. Rowe Price
- Details: T. Rowe Price is a global investment management firm. They led the Series D round for Tempus in March 2018.
- Investment Focus Areas: Financial services, technology, healthcare.
- Notable Investments: Facebook, Netflix, Moderna.
- Lingotto
- Details: Lingotto is an investment firm focusing on long-term investments. They have been listed as an investor in Tempus.
- Investment Focus Areas: Technology, healthcare.
- Notable Investments: Not publicly disclosed.
What's Next for Tempus?
Tempus is poised for significant growth with its recent acquisition of Ambry Genetics, expanding its capabilities in hereditary cancer screening and comprehensive genetic testing. This strategic move, supported by $300 million in debt financing from Ares Management, positions Tempus to capitalize on the growing demand for AI-enabled healthcare solutions.
Future fundraising opportunities seem promising, given the substantial financial backing and successful acquisition. However, integrating Ambry Genetics while managing substantial debt will be challenging. Navigating these complexities will be crucial for Tempus as it continues to innovate and expand its market presence.
Use Clay to Get Funding Data
Sales professionals, take advantage of Clay's platform to access comprehensive fundraising data on companies like Tempus and gather other critical business insights. Sign up for free today and elevate your sales strategy with the power of data-driven intelligence.
